Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Vikas Goyal
Non-invasive lower airway sampling in protracted bacterial bronchitis: Are we there yet?
Non-invasive lower airway sampling in protracted bacterial bronchitis: Are we there yet? Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Kuku Is Hiring 1,000 People For An AI Content Unit Ahead Of A ₹3,500 Crore IPO
In this storyKuku FM Kuku Technologies is building a 1,000-member AI-led content production unit in Mumbai, according to people familiar with the matter, as it prepares for a public listing. The company has hired close to 200 people for the unit and plans to reach around 1,000 by the end of the current financial year. It is recruiting writers, filmmakers and engineers into a single team.
Short and long-term effects of a play-based therapeutic exercise program in children with non-cystic fibrosis bronchiectasis: A randomised controlled trial
Keywords chronic respiratory disease paediatric exacerbation fundamental movement skills therapeutic exercise accelerometer developmentally appropriate play-based Practical implications • High adherence and enjoyment of supervised sessions indicate that structured, group-based delivery is a feasible and engaging approach for children with bronchiectasis.
Development of a preference weighting system for the parent proxy child chronic cough quality-of-life (PC-QoL) instrument
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes Preference-Based AssessmentsArticles in PressOpen access 1Australian Centre for Health Services Innovation, Centre for Healthcare Transformation, School of Public Health and Social Work, Queensland University of Technology, Brisbane 2NHMRC Centre for Research...
Clinical utility of elective paediatric flexible bronchoscopy and impact on the quality of life: protocol for a single-centre, single-blind, randomised controlled trial
Introduction Flexible bronchoscopy (FB) involves viewing the larynx and lower airways with a flexible bronchoscope. Bronchoalveolar lavage (BAL) is usually performed at the time of FB. BAL provides various details including cellular profile and microbiology of pathogens.
Cough in Protracted Bacterial Bronchitis and Bronchiectasis
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The utility of elective flexible bronchoscopy to improve quality of life and clinical outcomes for children: A systematic review
ATS American Thoracic Society BAL bronchoalveolar lavage CENTRAL Cochrane central register of controlled trials CT computed tomography DASS21 Depression anxiety and stress scale 21 ERS European Respiratory Society FB flexible bronchoscopy PCR polymerase chain reaction Peds-QL 4.0 Pediatric quality of life inventory 4.0 PROMs patient related outcome measures QoL quality of life RCT randomized controlled trial SR systematic review STAI state-trait anxiety inventory WHOICTRP World Health...
Query with regard to the Charitable trusts/society registered u/s 12AB/12AA - Tax queries - Income Tax
Query with regard to the Charitable trusts/society registered u/s 12AB/12AA One of the registered trusts has donated some amount to another trust which is registered u/s 12AB/12AA during the FY 2022-23. This amount donated is out of accumulated amount u/s 11(2) of the previous years (accumulation of FY2021-22 & prior). My queries in this regard are as under: 1. Does this transaction attract non-compliance of income tax u/s 11(3)(d)? 2.
Anthony Mancini of Genmab on Growing Your Company Together with Partners
Anthony Mancini is the chief operating officer of Denmark-based Genmab, one of the leading innovators of antibody therapies for patients living with cancer and other serious diseases. After many years working as a behind-the-scenes innovator, Genmab is now becoming a significant commercial entity. In 2021, the company began marketing its first commercial product, Tidvak® (tisotumab vedotin) for the treatment of advanced cervical cancer, in partnership with Seagen (acquisition by Pfizer pending).
Jan Skvarka, former Trillium CEO, on Driving a Turnaround
Jan Skvarka isn’t a household name in biotech. Maybe he should be. Skvarka was previously the CEO of Trillium Therapeutics, where he led a remarkable turnaround of the Canadian small cap biotech into a leading immune oncology player. Trillium had a market capitalization of $16 million when he started. Over the next two years, he led it to a $2.26 billion acquisition by Pfizer.
Adherence, reliability, and variability of home spirometry telemonitoring in cystic fibrosis
Introduction Cystic fibrosis (CF) is one of the most common severe autosomal recessive disease (1). CF is related to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes the CFTR epithelial ion channel involved in chloride and bicarbonate transport, leading to impaired mucus hydration and clearance (2).
James Mutamba of Arrakis on Negotiating a Big Amgen Deal at Warp Speed
James Mutamba is the chief business officer of Waltham, Mass.-based Arrakis Therapeutics. It’s a biotech developing small molecules against RNA targets. Arrakis struck its first major pharma partnership in 2020 with Roche. During the JP Morgan Healthcare Conference this past January, Arrakis announced another multi-target collaboration with Amgen to discover and develop small molecule RNA degraders, a new drug class which Arrakis calls nucleic acid targeting chimeras (NUTACs).
Why Kymab Agreed to be Acquired by Sanofi
UK-based Kymab made headlines back in January 2021. Sanofi agreed to acquire the antibody drug developer for $1.1 billion upfront, plus $350 million in potential milestones. The main attraction for Sanofi was KY1005, a monoclonal antibody targeting OX40L, a regulator of the immune system. Five months before the deal, Kymab announced it hit both primary endpoints of a Phase 2a trial of patients with moderate to severe atopic dermatitis that wasn’t responding to topical corticosteroids.
Ram Aiyar on Finding Deal Alignment Internally and Externally
Ram Aiyar is currently the CEO of Cambridge, Mass.-based Korro Bio, a company using RNA editing to treat genetic diseases, including Alpha-1 Antitrypsin Deficiency. Before he took that job, he was a founder and executive vice president of corporate and business development at Corvidia Therapeutics. That company was acquired by Novo Nordisk in August 2020 for $725 million upfront, and $2.1 billion total.
Bronchiectasis in Childhood
Chang A.B. Fortescue R. Grimwood K. et al. Task Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021; : 2002990 Kapur N. Masel J.P. Watson D. et al. Bronchoarterial ratio on high-resolution CT scan of the chest in children without pulmonary pathology: need to redefine bronchial dilatation. Chest.
Behind the Scenes of BD: Maude Tessier on a Megamerger Curveball
Vikas Goyal, former SVP, business development, Pandion Therapeutics (now part of Merck) [Editor’s Note: this is part of a series of interviews with business development executives about some of the surprises, subtleties, and human aspects of biotech dealmaking.] Maude Tessier is the chief business officer of Boston-based Ikena Oncology, a developer of targeted small molecule cancer drugs.
Behind the Scenes of BD: Brad Prosek on Getting to Know an Unconventional Acquirer
Vikas Goyal, former SVP, business development, Pandion Therapeutics (now part of Merck) [Editor’s Note: this is the first in a monthly series with business development executives about some of the surprises, subtleties, and human aspects of biotech dealmaking.] Cambridge, Mass.-based Constellation Pharmaceuticals lived through the ups and downs of the epigenetic drug discovery field for a decade, before it exited on a high note last year.
Duration of amoxicillin-clavulanate for protracted bacterial bronchitis in children (DACS): a multi-centre, double blind, randomised controlled trial
Summary Background Protracted bacterial bronchitis (PBB) is a leading cause of chronic wet cough in children. The current standard treatment in European and American guidelines is 2 weeks of antibiotics, but the optimal duration of therapy is unknown. We describe the first randomised controlled trial to assess the duration of antibiotic treatment in children with chronic wet cough and suspected PBB.
Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial - The Lancet Respiratory Medicine
Summary Background Bronchiectasis guidelines recommend antibiotics for the treatment of acute respiratory exacerbations, but randomised placebo-controlled trials in children are lacking. We hypothesised that oral amoxicillin–clavulanate and azithromycin would each be superior to placebo in achieving symptom resolution of non-severe exacerbations in children by day 14 of treatment.
Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial - The Lancet
Although amoxicillin–clavulanate is the recommended first-line empirical oral antibiotic treatment for non-severe exacerbations in children with bronchiectasis, azithromycin is also often prescribed for its convenient once-daily dosing. No randomised controlled trials involving acute exacerbations in children with bronchiectasis have been published to our knowledge.
Chronic cough postacute respiratory illness in children: a cohort study
Objective Data on the aetiology of persistent cough at the transitional stage from subacute to chronic cough (>4 weeks duration) are scarce. We aimed to (1) identify the prevalence of chronic cough following acute respiratory illness (ARI) and (2) determine the diagnostic outcomes of children with chronic cough. Patients Children aged <15?years presenting with an ARI with cough.
Chronic cough postacute respiratory illness in children: a cohort study
Objective Data on the aetiology of persistent cough at the transitional stage from subacute to chronic cough (>4 weeks duration) are scarce. We aimed to (1) identify the prevalence of chronic cough following acute respiratory illness (ARI) and (2) determine the diagnostic outcomes of children with chronic cough. Patients Children aged <15?years presenting with an ARI with cough.
Paediatric chronic suppurative lung disease: clinical characteristics and outcomes
Original ArticleEuropean Journal of Pediatrics pp 1-8First online: 11 June 2016Paediatric chronic suppurative lung disease: clinical characteristics and outcomesVikas GoyalAffiliated withCentre for Children’s Health Research, University of QueenslandDepartment of Respiratory and Sleep Medicine, Lady Cilento Children’s Hospital Email author View author's OrcID profile , Keith GrimwoodAffiliated withCentre for Children’s Health Research, University of QueenslandMenzies Health Institute...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Vikas
Contact Vikas, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack